Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting
Weiss C, Figueras Agustí E, Borbély AN, Sewald N (2017)
Journal of Peptide Science 23(7-8): 514-531.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Autor*in
Einrichtung
Abstract / Bemerkung
Cryptophycins are a class of 16-membered highly cytotoxic macrocyclic depsipeptides isolated from cyanobacteria. The biological activity is based on their ability to interact with tubulin. They interfere with microtubule dynamics and prevent microtubules from forming correct mitotic spindles, which causes cell-cycle arrest and apoptosis. Their strong antiproliferative activities with 100-fold to 1000-fold potency compared with those of paclitaxel and vinblastine have been observed. Cryptophycins are highly promising drug candidates, as their biological activity is not negatively affected by P-glycoprotein, a drug efflux system commonly found in multidrug-resistant cancer cell lines and solid tumors. Cryptophycin-52 had been investigated in phase II clinical trials but failed because of its high neurotoxicity. Recently, cryptophycin conjugates with peptides and antibodies have been developed for targeted delivery in tumor therapy. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
Stichworte
natural product;
depsipeptide;
total synthesis;
biological activity;
SAR;
antimitotic agent;
drug conjugate;
bioconjugation;
warhead
Erscheinungsjahr
2017
Zeitschriftentitel
Journal of Peptide Science
Band
23
Ausgabe
7-8
Seite(n)
514-531
Urheberrecht / Lizenzen
Konferenz
Conference on Rokko Mountain
Konferenzort
Kobe, JAPAN
ISSN
1075-2617
eISSN
1099-1387
Page URI
https://pub.uni-bielefeld.de/record/2916981
Zitieren
Weiss C, Figueras Agustí E, Borbély AN, Sewald N. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Journal of Peptide Science. 2017;23(7-8):514-531.
Weiss, C., Figueras Agustí, E., Borbély, A. N., & Sewald, N. (2017). Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Journal of Peptide Science, 23(7-8), 514-531. https://doi.org/10.1002/psc.3015
Weiss, Christine, Figueras Agustí, Eduard, Borbély, Adina Noémi, and Sewald, Norbert. 2017. “Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting”. Journal of Peptide Science 23 (7-8): 514-531.
Weiss, C., Figueras Agustí, E., Borbély, A. N., and Sewald, N. (2017). Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Journal of Peptide Science 23, 514-531.
Weiss, C., et al., 2017. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Journal of Peptide Science, 23(7-8), p 514-531.
C. Weiss, et al., “Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting”, Journal of Peptide Science, vol. 23, 2017, pp. 514-531.
Weiss, C., Figueras Agustí, E., Borbély, A.N., Sewald, N.: Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Journal of Peptide Science. 23, 514-531 (2017).
Weiss, Christine, Figueras Agustí, Eduard, Borbély, Adina Noémi, and Sewald, Norbert. “Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting”. Journal of Peptide Science 23.7-8 (2017): 514-531.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Public Domain Dedication (CC0 1.0):
Volltext(e)
Name
Access Level
Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:56Z
MD5 Prüfsumme
12444480cc16c7eb536dc3c102361967
Daten bereitgestellt von European Bioinformatics Institute (EBI)
8 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery.
Borbély A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N., Pharmaceutics 11(4), 2019
PMID: 30939768
Borbély A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N., Pharmaceutics 11(4), 2019
PMID: 30939768
Bacteria in Cancer Therapeutics: A Framework for Effective Therapeutic Bacterial Screening and Identification.
Ashu EE, Xu J, Yuan ZC., J Cancer 10(8), 2019
PMID: 31205534
Ashu EE, Xu J, Yuan ZC., J Cancer 10(8), 2019
PMID: 31205534
Octreotide Conjugates for Tumor Targeting and Imaging.
Figueras E, Martins A, Borbély A, Le Joncour V, Cordella P, Perego R, Modena D, Pagani P, Esposito S, Auciello G, Frese M, Gallinari P, Laakkonen P, Steinkühler C, Sewald N., Pharmaceutics 11(5), 2019
PMID: 31067748
Figueras E, Martins A, Borbély A, Le Joncour V, Cordella P, Perego R, Modena D, Pagani P, Esposito S, Auciello G, Frese M, Gallinari P, Laakkonen P, Steinkühler C, Sewald N., Pharmaceutics 11(5), 2019
PMID: 31067748
Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery.
Borbély A, Figueras E, Martins A, Bodero L, Raposo Moreira Dias A, López Rivas P, Pina A, Arosio D, Gallinari P, Frese M, Steinkühler C, Gennari C, Piarulli U, Sewald N., ChemistryOpen 8(6), 2019
PMID: 31275795
Borbély A, Figueras E, Martins A, Bodero L, Raposo Moreira Dias A, López Rivas P, Pina A, Arosio D, Gallinari P, Frese M, Steinkühler C, Gennari C, Piarulli U, Sewald N., ChemistryOpen 8(6), 2019
PMID: 31275795
Novel unit B cryptophycin analogues as payloads for targeted therapy.
Figueras E, Borbély A, Ismail M, Frese M, Sewald N., Beilstein J Org Chem 14(), 2018
PMID: 29977395
Figueras E, Borbély A, Ismail M, Frese M, Sewald N., Beilstein J Org Chem 14(), 2018
PMID: 29977395
Cyanopeptolins with Trypsin and Chymotrypsin Inhibitory Activity from the Cyanobacterium Nostoc edaphicum CCNP1411.
Mazur-Marzec H, Fidor A, Cegłowska M, Wieczerzak E, Kropidłowska M, Goua M, Macaskill J, Edwards C., Mar Drugs 16(7), 2018
PMID: 29949853
Mazur-Marzec H, Fidor A, Cegłowska M, Wieczerzak E, Kropidłowska M, Goua M, Macaskill J, Edwards C., Mar Drugs 16(7), 2018
PMID: 29949853
Reviving old protecting group chemistry for site-selective peptide-protein conjugation.
Gunnoo SB, Iyer A, Vannecke W, Decoene KW, Hebbrecht T, Gettemans J, Laga M, Loverix S, Lasters I, Madder A., Chem Commun (Camb) 54(84), 2018
PMID: 30285017
Gunnoo SB, Iyer A, Vannecke W, Decoene KW, Hebbrecht T, Gettemans J, Laga M, Loverix S, Lasters I, Madder A., Chem Commun (Camb) 54(84), 2018
PMID: 30285017
In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas.
Cazzamalli S, Figueras E, Pethő L, Borbély A, Steinkühler C, Neri D, Sewald N., ACS Omega 3(11), 2018
PMID: 30533574
Cazzamalli S, Figueras E, Pethő L, Borbély A, Steinkühler C, Neri D, Sewald N., ACS Omega 3(11), 2018
PMID: 30533574
125 References
Daten bereitgestellt von Europe PubMed Central.
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blattler WA, Chari RV., Proc. Natl. Acad. Sci. U.S.A. 93(16), 1996
PMID: 8710920
Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blattler WA, Chari RV., Proc. Natl. Acad. Sci. U.S.A. 93(16), 1996
PMID: 8710920
Antibody-drug conjugates in tumor therapy.
Sammet B, Steinkuhler C, Sewald N., Pharm Pat Anal 1(1), 2012
PMID: 24236714
Sammet B, Steinkuhler C, Sewald N., Pharm Pat Anal 1(1), 2012
PMID: 24236714
Sewald, 2015
Antibody-drug conjugates: an emerging concept in cancer therapy.
Chari RV, Miller ML, Widdison WC., Angew. Chem. Int. Ed. Engl. 53(15), 2014
PMID: 24677743
Chari RV, Miller ML, Widdison WC., Angew. Chem. Int. Ed. Engl. 53(15), 2014
PMID: 24677743
Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line.
Coradini D, Pellizzaro C, Miglierini G, Daidone MG, Perbellini A., Int. J. Cancer 81(3), 1999
PMID: 10209956
Coradini D, Pellizzaro C, Miglierini G, Daidone MG, Perbellini A., Int. J. Cancer 81(3), 1999
PMID: 10209956
Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate.
Luo Y, Prestwich GD., Bioconjug. Chem. 10(5), 1999
PMID: 10502340
Luo Y, Prestwich GD., Bioconjug. Chem. 10(5), 1999
PMID: 10502340
A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells.
Luo Y, Ziebell MR, Prestwich GD., Biomacromolecules 1(2), 2000
PMID: 11710102
Luo Y, Ziebell MR, Prestwich GD., Biomacromolecules 1(2), 2000
PMID: 11710102
Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD., Pharm. Res. 19(4), 2002
PMID: 12033370
Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD., Pharm. Res. 19(4), 2002
PMID: 12033370
Small Molecules for Active Targeting in Cancer.
Kue CS, Kamkaew A, Burgess K, Kiew LV, Chung LY, Lee HB., Med Res Rev 36(3), 2016
PMID: 26992114
Kue CS, Kamkaew A, Burgess K, Kiew LV, Chung LY, Lee HB., Med Res Rev 36(3), 2016
PMID: 26992114
Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
Eliaz RE, Szoka FC Jr., Cancer Res. 61(6), 2001
PMID: 11289136
Eliaz RE, Szoka FC Jr., Cancer Res. 61(6), 2001
PMID: 11289136
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S., Adv. Drug Deliv. Rev. 56(8), 2004
PMID: 15094214
Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S., Adv. Drug Deliv. Rev. 56(8), 2004
PMID: 15094214
Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer.
Hattori Y, Maitani Y., J Control Release 97(1), 2004
PMID: 15147814
Hattori Y, Maitani Y., J Control Release 97(1), 2004
PMID: 15147814
Drug delivery and release systems for targeted tumor therapy.
Bohme D, Beck-Sickinger AG., J. Pept. Sci. 21(3), 2015
PMID: 25703117
Bohme D, Beck-Sickinger AG., J. Pept. Sci. 21(3), 2015
PMID: 25703117
Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C., Chemistry 21(18), 2015
PMID: 25784522
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C., Chemistry 21(18), 2015
PMID: 25784522
Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells.
Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G., Biopolymers 106(2), 2016
PMID: 26715008
Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G., Biopolymers 106(2), 2016
PMID: 26715008
Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G., Bioorg. Med. Chem. 24(2), 2015
PMID: 26719208
Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G., Bioorg. Med. Chem. 24(2), 2015
PMID: 26719208
Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z., Mol. Pharm. 8(2), 2011
PMID: 21241067
Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z., Mol. Pharm. 8(2), 2011
PMID: 21241067
Double Methotrexate-Modified Neuropeptide Y Analogues Express Increased Toxicity and Overcome Drug Resistance in Breast Cancer Cells.
Bohme D, Krieghoff J, Beck-Sickinger AG., J. Med. Chem. 59(7), 2016
PMID: 26985967
Bohme D, Krieghoff J, Beck-Sickinger AG., J. Med. Chem. 59(7), 2016
PMID: 26985967
Recent advances in tumor-targeting anticancer drug conjugates.
Jaracz S, Chen J, Kuznetsova LV, Ojima I., Bioorg. Med. Chem. 13(17), 2005
PMID: 15955702
Jaracz S, Chen J, Kuznetsova LV, Ojima I., Bioorg. Med. Chem. 13(17), 2005
PMID: 15955702
Taxol and other microtubule-interacting agents
Fojo, Curr. Opin. Oncol. Endocr. Metab. Investig. Drugs 2(), 2000
Fojo, Curr. Opin. Oncol. Endocr. Metab. Investig. Drugs 2(), 2000
Microtubule-interacting drugs for cancer treatment.
Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC., Trends Pharmacol. Sci. 24(7), 2003
PMID: 12871669
Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC., Trends Pharmacol. Sci. 24(7), 2003
PMID: 12871669
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D, Bronte G, Passiglia F, Calo V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listi A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V., Anal Cell Pathol (Amst) 2015(), 2015
PMID: 26484003
Fanale D, Bronte G, Passiglia F, Calo V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listi A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V., Anal Cell Pathol (Amst) 2015(), 2015
PMID: 26484003
Arrangement of subunits in flagellar microtubules.
Amos L, Klug A., J. Cell. Sci. 14(3), 1974
PMID: 4830832
Amos L, Klug A., J. Cell. Sci. 14(3), 1974
PMID: 4830832
Chromosome-microtubule interactions during mitosis.
McIntosh JR, Grishchuk EL, West RR., Annu. Rev. Cell Dev. Biol. 18(), 2002
PMID: 12142285
McIntosh JR, Grishchuk EL, West RR., Annu. Rev. Cell Dev. Biol. 18(), 2002
PMID: 12142285
Microtubule polymerization dynamics.
Desai A, Mitchison TJ., Annu. Rev. Cell Dev. Biol. 13(), 1997
PMID: 9442869
Desai A, Mitchison TJ., Annu. Rev. Cell Dev. Biol. 13(), 1997
PMID: 9442869
Tubulin rings: which way do they curve?
Nogales E, Wang HW, Niederstrasser H., Curr. Opin. Struct. Biol. 13(2), 2003
PMID: 12727521
Nogales E, Wang HW, Niederstrasser H., Curr. Opin. Struct. Biol. 13(2), 2003
PMID: 12727521
Microtubules as a target for anticancer drugs.
Jordan MA, Wilson L., Nat. Rev. Cancer 4(4), 2004
PMID: 15057285
Jordan MA, Wilson L., Nat. Rev. Cancer 4(4), 2004
PMID: 15057285
Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics.
Downing KH., Annu. Rev. Cell Dev. Biol. 16(), 2000
PMID: 11031231
Downing KH., Annu. Rev. Cell Dev. Biol. 16(), 2000
PMID: 11031231
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff PB, Horwitz SB., Proc. Natl. Acad. Sci. U.S.A. 77(3), 1980
PMID: 6103535
Schiff PB, Horwitz SB., Proc. Natl. Acad. Sci. U.S.A. 77(3), 1980
PMID: 6103535
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan MA, Toso RJ, Thrower D, Wilson L., Proc. Natl. Acad. Sci. U.S.A. 90(20), 1993
PMID: 8105478
Jordan MA, Toso RJ, Thrower D, Wilson L., Proc. Natl. Acad. Sci. U.S.A. 90(20), 1993
PMID: 8105478
Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.
Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L., Cancer Res. 56(4), 1996
PMID: 8631019
Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L., Cancer Res. 56(4), 1996
PMID: 8631019
Substoichiometric binding of taxol suppresses microtubule dynamics.
Derry WB, Wilson L, Jordan MA., Biochemistry 34(7), 1995
PMID: 7857932
Derry WB, Wilson L, Jordan MA., Biochemistry 34(7), 1995
PMID: 7857932
Taxol suppresses dynamics of individual microtubules in living human tumor cells.
Yvon AM, Wadsworth P, Jordan MA., Mol. Biol. Cell 10(4), 1999
PMID: 10198049
Yvon AM, Wadsworth P, Jordan MA., Mol. Biol. Cell 10(4), 1999
PMID: 10198049
Pharmaceuticals from cultured algae
Schwartz, J. Ind. Microbiol. 5(), 1990
Schwartz, J. Ind. Microbiol. 5(), 1990
Biosynthetic characterization and chemoenzymatic assembly of the cryptophycins. Potent anticancer agents from cyanobionts.
Magarvey NA, Beck ZQ, Golakoti T, Ding Y, Huber U, Hemscheidt TK, Abelson D, Moore RE, Sherman DH., ACS Chem. Biol. 1(12), 2006
PMID: 17240975
Magarvey NA, Beck ZQ, Golakoti T, Ding Y, Huber U, Hemscheidt TK, Abelson D, Moore RE, Sherman DH., ACS Chem. Biol. 1(12), 2006
PMID: 17240975
Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224
Golakoti, J. Am. Chem. Soc. 117(), 1995
Golakoti, J. Am. Chem. Soc. 117(), 1995
Secondary metabolites from cyanobacteria: complex structures and powerful bioactivities
Gademann, Curr Org. Chem. 12(), 2008
Gademann, Curr Org. Chem. 12(), 2008
Marine cyanobacteria - a prolific source of natural products
Burja, Tetrahedron 57(), 2001
Burja, Tetrahedron 57(), 2001
AUTHOR UNKNOWN, 0
Evaluation of Nostoc strain ATCC 53789 as a potential source of natural pesticides.
Biondi N, Piccardi R, Margheri MC, Rodolfi L, Smith GD, Tredici MR., Appl. Environ. Microbiol. 70(6), 2004
PMID: 15184126
Biondi N, Piccardi R, Margheri MC, Rodolfi L, Smith GD, Tredici MR., Appl. Environ. Microbiol. 70(6), 2004
PMID: 15184126
Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224
Trimurtulu, J. Am. Chem. Soc. 116(), 1994
Trimurtulu, J. Am. Chem. Soc. 116(), 1994
The absolute stereostructure of arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria
Kobayashi, Chem. Pharm. Bull. 42(), 1994
Kobayashi, Chem. Pharm. Bull. 42(), 1994
Arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria
Kobayashi, Tetrahedron Lett. 35(), 1994
Kobayashi, Tetrahedron Lett. 35(), 1994
Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV, Golakoti T, Patterson GM, Moore RE., J. Nat. Prod. 60(3), 1997
PMID: 9090872
Subbaraju GV, Golakoti T, Patterson GM, Moore RE., J. Nat. Prod. 60(3), 1997
PMID: 9090872
Isolation and structure determination of cryptophycins 38, 326, and 327 from the terrestrial cyanobacterium Nostoc sp. GSV 224.
Chaganty S, Golakoti T, Heltzel C, Moore RE, Yoshida WY., J. Nat. Prod. 67(8), 2004
PMID: 15332864
Chaganty S, Golakoti T, Heltzel C, Moore RE, Yoshida WY., J. Nat. Prod. 67(8), 2004
PMID: 15332864
The synthesis of cryptophycins
Eißler, Synthesis (), 2006
Eißler, Synthesis (), 2006
Recent approaches for the synthesis of modified cryptophycins.
Weiss C, Sammet B, Sewald N., Nat Prod Rep 30(7), 2013
PMID: 23732943
Weiss C, Sammet B, Sewald N., Nat Prod Rep 30(7), 2013
PMID: 23732943
Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E., Cancer Res. 56(19), 1996
PMID: 8813133
Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E., Cancer Res. 56(19), 1996
PMID: 8813133
Cellular uptake of a novel cytotoxic agent, cryptophycin-52, by human THP-1 leukemia cells and H-125 lung tumor cells.
Chen BD, Nakeff A, Valeriote F., Int. J. Cancer 77(6), 1998
PMID: 9714056
Chen BD, Nakeff A, Valeriote F., Int. J. Cancer 77(6), 1998
PMID: 9714056
Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH., FEBS Lett. 377(1), 1995
PMID: 8543019
Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH., FEBS Lett. 377(1), 1995
PMID: 8543019
Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith CD, Zhang X., J. Biol. Chem. 271(11), 1996
PMID: 8626409
Smith CD, Zhang X., J. Biol. Chem. 271(11), 1996
PMID: 8626409
Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL, Taoka CR, Busquets L., Cancer Lett. 107(1), 1996
PMID: 8913266
Mooberry SL, Taoka CR, Busquets L., Cancer Lett. 107(1), 1996
PMID: 8913266
Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R, Durso NA, Sackett DL, Hamel E., Biochemistry 38(43), 1999
PMID: 10572005
Bai R, Durso NA, Sackett DL, Hamel E., Biochemistry 38(43), 1999
PMID: 10572005
Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
Mitra A, Sept D., Biochemistry 43(44), 2004
PMID: 15518544
Mitra A, Sept D., Biochemistry 43(44), 2004
PMID: 15518544
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL, Pettit GR, Hamel E., J. Biol. Chem. 265(28), 1990
PMID: 2211617
Bai RL, Pettit GR, Hamel E., J. Biol. Chem. 265(28), 1990
PMID: 2211617
Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, Wilson L., Biochemistry 39(46), 2000
PMID: 11087360
Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, Wilson L., Biochemistry 39(46), 2000
PMID: 11087360
Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D, Himes RH, Moore RE, Wilson L, Jordan MA., Biochemistry 36(42), 1997
PMID: 9335554
Panda D, Himes RH, Moore RE, Wilson L, Jordan MA., Biochemistry 36(42), 1997
PMID: 9335554
In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
Barbier P, Gregoire C, Devred F, Sarrazin M, Peyrot V., Biochemistry 40(45), 2001
PMID: 11695898
Barbier P, Gregoire C, Devred F, Sarrazin M, Peyrot V., Biochemistry 40(45), 2001
PMID: 11695898
Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D, DeLuca K, Williams D, Jordan MA, Wilson L., Proc. Natl. Acad. Sci. U.S.A. 95(16), 1998
PMID: 9689077
Panda D, DeLuca K, Williams D, Jordan MA, Wilson L., Proc. Natl. Acad. Sci. U.S.A. 95(16), 1998
PMID: 9689077
The cryptophycin-tubulin ring structure indicates two points of curvature in the tubulin dimer.
Watts NR, Cheng N, West W, Steven AC, Sackett DL., Biochemistry 41(42), 2002
PMID: 12379108
Watts NR, Cheng N, West W, Steven AC, Sackett DL., Biochemistry 41(42), 2002
PMID: 12379108
Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent.
Mooberry SL, Busquets L, Tien G., Int. J. Cancer 73(3), 1997
PMID: 9359493
Mooberry SL, Busquets L, Tien G., Int. J. Cancer 73(3), 1997
PMID: 9359493
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP., Clin. Cancer Res. 8(12), 2002
PMID: 12473608
Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP., Clin. Cancer Res. 8(12), 2002
PMID: 12473608
Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE., Cancer Res. 54(14), 1994
PMID: 7913408
Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE., Cancer Res. 54(14), 1994
PMID: 7913408
Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells.
Lu K, Dempsey J, Schultz RM, Shih C, Teicher BA., Cancer Chemother. Pharmacol. 47(2), 2001
PMID: 11269744
Lu K, Dempsey J, Schultz RM, Shih C, Teicher BA., Cancer Chemother. Pharmacol. 47(2), 2001
PMID: 11269744
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C, Teicher BA., Curr. Pharm. Des. 7(13), 2001
PMID: 11472266
Shih C, Teicher BA., Curr. Pharm. Des. 7(13), 2001
PMID: 11472266
Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance.
Yuan H, Li X, Wu J, Li J, Qu X, Xu W, Tang W., Curr. Med. Chem. 15(5), 2008
PMID: 18289002
Yuan H, Li X, Wu J, Li J, Qu X, Xu W, Tang W., Curr. Med. Chem. 15(5), 2008
PMID: 18289002
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G., Science 323(5922), 2009
PMID: 19325113
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G., Science 323(5922), 2009
PMID: 19325113
Cryptophycin 1 cellular levels and effects in vitro using L1210 cells.
Foster BJ, Fortuna M, Media J, Wiegand RA, Valeriote FA., Invest New Drugs 16(3), 1998
PMID: 10360599
Foster BJ, Fortuna M, Media J, Wiegand RA, Valeriote FA., Invest New Drugs 16(3), 1998
PMID: 10360599
Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K, Alvarez E, Forler P, Phares V, Amsrud T, Shih C, Al-Awar R, Teicher BA., Cancer Chemother. Pharmacol. 46(2), 2000
PMID: 10972484
Menon K, Alvarez E, Forler P, Phares V, Amsrud T, Shih C, Al-Awar R, Teicher BA., Cancer Chemother. Pharmacol. 46(2), 2000
PMID: 10972484
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ., Clin. Cancer Res. 8(8), 2002
PMID: 12171879
Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ., Clin. Cancer Res. 8(8), 2002
PMID: 12171879
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C, Weigang-Kohler K, Pagani O, Greim G, Mora O, De Pas T, Burgess M, Weimer I, Johnson R., Eur. J. Cancer 38(18), 2002
PMID: 12460783
Sessa C, Weigang-Kohler K, Pagani O, Greim G, Mora O, De Pas T, Burgess M, Weimer I, Johnson R., Eur. J. Cancer 38(18), 2002
PMID: 12460783
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
D'Agostino G, del Campo J, Mellado B, Izquierdo MA, Minarik T, Cirri L, Marini L, Perez-Gracia JL, Scambia G., Int. J. Gynecol. Cancer 16(1), 2006
PMID: 16445613
D'Agostino G, del Campo J, Mellado B, Izquierdo MA, Minarik T, Cirri L, Marini L, Perez-Gracia JL, Scambia G., Int. J. Gynecol. Cancer 16(1), 2006
PMID: 16445613
Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR, Polin L, Zhou SL, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE., Cancer Chemother. Pharmacol. 52(1), 2003
PMID: 12739061
Boinpally RR, Polin L, Zhou SL, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE., Cancer Chemother. Pharmacol. 52(1), 2003
PMID: 12739061
The search for new antitumor drugs from blue-green algae
Moore, Curr. Pharm. Des. 2(), 1996
Moore, Curr. Pharm. Des. 2(), 1996
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J, Moore RE, Moher ED, Munroe JE, Al-awar RS, Hay DA, Varie DL, Zhang TY, Aikins JA, Martinelli MJ, Shih C, Ray JE, Gibson LL, Vasudevan V, Polin L, White K, Kushner J, Simpson C, Pugh S, Corbett TH., Invest New Drugs 23(3), 2005
PMID: 15868377
Liang J, Moore RE, Moher ED, Munroe JE, Al-awar RS, Hay DA, Varie DL, Zhang TY, Aikins JA, Martinelli MJ, Shih C, Ray JE, Gibson LL, Vasudevan V, Polin L, White K, Kushner J, Simpson C, Pugh S, Corbett TH., Invest New Drugs 23(3), 2005
PMID: 15868377
Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide.
Kobayashi M, Wang W, Ohyabu N, Kurosu M, Kitagawa I., Chem. Pharm. Bull. 43(9), 1995
PMID: 7586087
Kobayashi M, Wang W, Ohyabu N, Kurosu M, Kitagawa I., Chem. Pharm. Bull. 43(9), 1995
PMID: 7586087
Synthesis and in vitro cytotoxicity of cryptophycins and related analogs
Muys, Bioorg. Med. Chem. Lett. 6(), 1996
Muys, Bioorg. Med. Chem. Lett. 6(), 1996
AUTHOR UNKNOWN, 0
Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues.
Patel VF, Andis SL, Kennedy JH, Ray JE, Schultz RM., J. Med. Chem. 42(14), 1999
PMID: 10411479
Patel VF, Andis SL, Kennedy JH, Ray JE, Schultz RM., J. Med. Chem. 42(14), 1999
PMID: 10411479
Halohydrin analogues of cryptophycin 1: synthesis and biological activity.
Georg GI, Ali SM, Stella VJ, Waugh WN, Himes RH., Bioorg. Med. Chem. Lett. 8(15), 1998
PMID: 9873466
Georg GI, Ali SM, Stella VJ, Waugh WN, Himes RH., Bioorg. Med. Chem. Lett. 8(15), 1998
PMID: 9873466
Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Al-Awar RS, Corbett TH, Ray JE, Polin L, Kennedy JH, Wagner MM, Williams DC., Mol. Cancer Ther. 3(9), 2004
PMID: 15367700
Al-Awar RS, Corbett TH, Ray JE, Polin L, Kennedy JH, Wagner MM, Williams DC., Mol. Cancer Ther. 3(9), 2004
PMID: 15367700
AUTHOR UNKNOWN, 0
Design and synthesis of a new class of cryptophycins based tubulin inhibitors.
Kumar A, Kumar M, Sharma S, Guru SK, Bhushan S, Shah BA., Eur J Med Chem 93(), 2015
PMID: 25647428
Kumar A, Kumar M, Sharma S, Guru SK, Bhushan S, Shah BA., Eur J Med Chem 93(), 2015
PMID: 25647428
A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS, Ray JE, Schultz RM, Andis SL, Kennedy JH, Moore RE, Liang J, Golakoti T, Subbaraju GV, Corbett TH., J. Med. Chem. 46(14), 2003
PMID: 12825938
Al-Awar RS, Ray JE, Schultz RM, Andis SL, Kennedy JH, Moore RE, Liang J, Golakoti T, Subbaraju GV, Corbett TH., J. Med. Chem. 46(14), 2003
PMID: 12825938
Efficient synthesis of cryptophycin-52 and novel para-alkoxymethyl unit A analogues.
Eissler S, Bogner T, Nahrwold M, Sewald N., Chemistry 15(42), 2009
PMID: 19760734
Eissler S, Bogner T, Nahrwold M, Sewald N., Chemistry 15(42), 2009
PMID: 19760734
The remarkable transport mechanism of P-glycoprotein: a multidrug transporter.
Al-Shawi MK, Omote H., J. Bioenerg. Biomembr. 37(6), 2005
PMID: 16691488
Al-Shawi MK, Omote H., J. Bioenerg. Biomembr. 37(6), 2005
PMID: 16691488
Multiple molecular mechanisms for multidrug resistance transporters.
Higgins CF., Nature 446(7137), 2007
PMID: 17429392
Higgins CF., Nature 446(7137), 2007
PMID: 17429392
Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB, Huff JK, Himes RH, Georg GI., J. Med. Chem. 47(3), 2004
PMID: 14736249
Buck SB, Huff JK, Himes RH, Georg GI., J. Med. Chem. 47(3), 2004
PMID: 14736249
Synthesis and cytotoxicity studies of new cryptophycin analogues.
Liu WL, Zhang JC, Jiang FQ, Fu L., Arch. Pharm. (Weinheim) 342(10), 2009
PMID: 19714674
Liu WL, Zhang JC, Jiang FQ, Fu L., Arch. Pharm. (Weinheim) 342(10), 2009
PMID: 19714674
The growing impact of click chemistry on drug discovery.
Kolb HC, Sharpless KB., Drug Discov. Today 8(24), 2003
PMID: 14678739
Kolb HC, Sharpless KB., Drug Discov. Today 8(24), 2003
PMID: 14678739
Peptidomimetics via copper-catalyzed azide-alkyne cycloadditions.
Angell YL, Burgess K., Chem Soc Rev 36(10), 2007
PMID: 17721589
Angell YL, Burgess K., Chem Soc Rev 36(10), 2007
PMID: 17721589
Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluation.
Mesenzani O, Massarotti A, Giustiniano M, Pirali T, Bevilacqua V, Caldarelli A, Canonico P, Sorba G, Novellino E, Genazzani AA, Tron GC., Bioorg. Med. Chem. Lett. 21(2), 2010
PMID: 21167709
Mesenzani O, Massarotti A, Giustiniano M, Pirali T, Bevilacqua V, Caldarelli A, Canonico P, Sorba G, Novellino E, Genazzani AA, Tron GC., Bioorg. Med. Chem. Lett. 21(2), 2010
PMID: 21167709
Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors.
Brik A, Muldoon J, Lin YC, Elder JH, Goodsell DS, Olson AJ, Fokin VV, Sharpless KB, Wong CH., Chembiochem 4(11), 2003
PMID: 14613121
Brik A, Muldoon J, Lin YC, Elder JH, Goodsell DS, Olson AJ, Fokin VV, Sharpless KB, Wong CH., Chembiochem 4(11), 2003
PMID: 14613121
1,2,3-Triazoles as peptide bond isosteres: synthesis and biological evaluation of cyclotetrapeptide mimics.
Bock VD, Speijer D, Hiemstra H, van Maarseveen JH., Org. Biomol. Chem. 5(6), 2007
PMID: 17340013
Bock VD, Speijer D, Hiemstra H, van Maarseveen JH., Org. Biomol. Chem. 5(6), 2007
PMID: 17340013
Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues.
Beierle JM, Horne WS, van Maarseveen JH, Waser B, Reubi JC, Ghadiri MR., Angew. Chem. Int. Ed. Engl. 48(26), 2009
PMID: 19266506
Beierle JM, Horne WS, van Maarseveen JH, Waser B, Reubi JC, Ghadiri MR., Angew. Chem. Int. Ed. Engl. 48(26), 2009
PMID: 19266506
"Clicktophycin-52": a bioactive cryptophycin-52 triazole analogue.
Nahrwold M, Bogner T, Eissler S, Verma S, Sewald N., Org. Lett. 12(5), 2010
PMID: 20131817
Nahrwold M, Bogner T, Eissler S, Verma S, Sewald N., Org. Lett. 12(5), 2010
PMID: 20131817
Interaction of arenastatin A with porcine brain tubulin.
Morita K, Koiso Y, Hashimoto Y, Kobayashi M, Wang W, Ohyabu N, Iwasaki S., Biol. Pharm. Bull. 20(2), 1997
PMID: 9057981
Morita K, Koiso Y, Hashimoto Y, Kobayashi M, Wang W, Ohyabu N, Iwasaki S., Biol. Pharm. Bull. 20(2), 1997
PMID: 9057981
Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).
Varie DL, Shih C, Hay DA, Andis SL, Corbett TH, Gossett LS, Janisse SK, Martinelli MJ, Moher ED, Schultz RM, Toth JE., Bioorg. Med. Chem. Lett. 9(3), 1999
PMID: 10091686
Varie DL, Shih C, Hay DA, Andis SL, Corbett TH, Gossett LS, Janisse SK, Martinelli MJ, Moher ED, Schultz RM, Toth JE., Bioorg. Med. Chem. Lett. 9(3), 1999
PMID: 10091686
Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region.
Shih C, Gossett LS, Gruber JM, Grossman CS, Andis SL, Schultz RM, Worzalla JF, Corbett TH, Metz JT., Bioorg. Med. Chem. Lett. 9(1), 1999
PMID: 9990459
Shih C, Gossett LS, Gruber JM, Grossman CS, Andis SL, Schultz RM, Worzalla JF, Corbett TH, Metz JT., Bioorg. Med. Chem. Lett. 9(1), 1999
PMID: 9990459
Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis.
Nahrwold M, Weiß C, Bogner T, Mertink F, Conradi J, Sammet B, Palmisano R, Royo Gracia S, Preuße T, Sewald N., J. Med. Chem. 56(5), 2013
PMID: 23387527
Nahrwold M, Weiß C, Bogner T, Mertink F, Conradi J, Sammet B, Palmisano R, Royo Gracia S, Preuße T, Sewald N., J. Med. Chem. 56(5), 2013
PMID: 23387527
Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.
Buck SB, Huff JK, Himes RH, Georg GI., J. Med. Chem. 47(14), 2004
PMID: 15214797
Buck SB, Huff JK, Himes RH, Georg GI., J. Med. Chem. 47(14), 2004
PMID: 15214797
Synthesis of stable analogs in blood and conformational analysis of arenastatin A, a potent cytotoxic spongean depsipeptide
Murakami, Tetrahedron 57(), 2001
Murakami, Tetrahedron 57(), 2001
Approaches for the synthesis of functionalized cryptophycins.
Sammet B, Bogner T, Nahrwold M, Weiss C, Sewald N., J. Org. Chem. 75(20), 2010
PMID: 20857920
Sammet B, Bogner T, Nahrwold M, Weiss C, Sewald N., J. Org. Chem. 75(20), 2010
PMID: 20857920
P-glycoprotein recognition of substrates and circumvention through rational drug design.
Raub TJ., Mol. Pharm. 3(1), 2006
PMID: 16686365
Raub TJ., Mol. Pharm. 3(1), 2006
PMID: 16686365
Total synthesis of cryptophycin analogues. Isosteric replacement of the C-D ester
Norman, J. Org. Chem. 63(), 1998
Norman, J. Org. Chem. 63(), 1998
Synthesis of amide analogs of arenastatin A
Murakami, Tetrahedron 56(), 2000
Murakami, Tetrahedron 56(), 2000
Synthesis of 15,20-triamide analogue with polar substituent on the phenyl ring of arenastatin A, an extremely potent cytotoxic spongean depsipeptide.
Kotoku N, Kato T, Narumi F, Ohtani E, Kamada S, Aoki S, Okada N, Nakagawa S, Kobayashi M., Bioorg. Med. Chem. 14(22), 2006
PMID: 16877000
Kotoku N, Kato T, Narumi F, Ohtani E, Kamada S, Aoki S, Okada N, Nakagawa S, Kobayashi M., Bioorg. Med. Chem. 14(22), 2006
PMID: 16877000
Fluorine in pharmaceuticals: looking beyond intuition.
Muller K, Faeh C, Diederich F., Science 317(5846), 2007
PMID: 17901324
Muller K, Faeh C, Diederich F., Science 317(5846), 2007
PMID: 17901324
Fluorine in medicinal chemistry: a review of anti-cancer agents
Isanbor, J. Fluor. Chem. 127(), 2006
Isanbor, J. Fluor. Chem. 127(), 2006
Recent advances (1995-2005) in fluorinated pharmaceuticals based on natural products
Bégué, J. Fluor. Chem. 127(), 2006
Bégué, J. Fluor. Chem. 127(), 2006
Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules
Kirk, J. Fluor. Chem. 127(), 2006
Kirk, J. Fluor. Chem. 127(), 2006
Kirsch, 2004
Odor-structure relationships using fluorine as a probe
Michel, Tetrahedron 56(), 2000
Michel, Tetrahedron 56(), 2000
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Total synthesis and biological evaluation of fluorinated cryptophycins.
Weiß C, Bogner T, Sammet B, Sewald N., Beilstein J Org Chem 8(), 2012
PMID: 23209540
Weiß C, Bogner T, Sammet B, Sewald N., Beilstein J Org Chem 8(), 2012
PMID: 23209540
Epothilone A and B - novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution
Höfle, Angew. Chem. Int. Ed. 35(), 1996
Höfle, Angew. Chem. Int. Ed. 35(), 1996
Synthesis of cryptothilone 1, the first cryptophycin-epothilone hybrid.
White JD, Smits H, Hamel E., Org. Lett. 8(18), 2006
PMID: 16928045
White JD, Smits H, Hamel E., Org. Lett. 8(18), 2006
PMID: 16928045
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
The cryptophycins as potent payloads for antibody drug conjugates.
Verma VA, Pillow TH, DePalatis L, Li G, Phillips GL, Polson AG, Raab HE, Spencer S, Zheng B., Bioorg. Med. Chem. Lett. 25(4), 2015
PMID: 25613677
Verma VA, Pillow TH, DePalatis L, Li G, Phillips GL, Polson AG, Raab HE, Spencer S, Zheng B., Bioorg. Med. Chem. Lett. 25(4), 2015
PMID: 25613677
AUTHOR UNKNOWN, 0
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 28661555
PubMed | Europe PMC
Suchen in
Google Scholar